Treating breakthrough pain in oncology

References

• Portenoy RK, Hagen NA. Breakthrough pain: definition, prevalence and characteristics. Pain. 1990;41:273–281.
   Web of Science ®Google Scholar
• Mercadante S. Breakthrough pain in cancer patients: prevalence, mechanisms and treatment options. Curr Opin Anaesthesiol. 2015;28:559–564.
   PubMed Web of Science ®Google Scholar
• Deandrea S, Corli O, Consonni D, et al. Prevalence of breakthrough cancer pain: a systematic review and a pooled analysis of published literature. J Pain Symptom Manage. 2014;47:57–76.
   PubMed Web of Science ®Google Scholar
• Mercadante S, Cuomo A. Breakthrough cancer pain: ten commandments. Value Health. 2016;19:531–536.
   PubMed Web of Science ®Google Scholar
• Davies AN, Dickman A, Reid C, et al. Science Committee of the Association for Palliative Medicine of Great Britain and Ireland. The management of cancer-related breakthrough pain: recommendations of a task group of the Science Committee of the Association for Palliative Medicine of Great Britain and Ireland. Eur J Pain. 2009;13:331–338.
   PubMed Web of Science ®Google Scholar
• Mercadante S, Portenoy RK. Breakthrough cancer pain: twenty-five years of study. Pain. 2016;157:2657–2663.
   PubMed Web of Science ®Google Scholar
• Mercadante S, Lazzari M, Reale C, et al. Italian Oncological Pain Survey (IOPS): a multicentre Italian study of breakthrough pain performed in different settings. Clin J Pain. 2015;31:214–221.
   PubMed Web of Science ®Google Scholar
• Mercadante S, Marchetti P, Cuomo A, et al. Breakthrough cancer pain: preliminary data of the Italian Oncologic Pain Multisetting Multicentric Survey (IOPS-MS). Adv Ther. 2017;120–135.
   PubMed Web of Science ®Google Scholar
• Haugen D, Hjermstad M, Hagen N, et al. Assessment and classification of cancer breakthrough pain: a systematic literature review. Pain. 2010;141:476–482.
   PubMed Web of Science ®Google Scholar
• Hjermstad MJ, Kaasa S, Caraceni A, et al. Characteristics of breakthrough cancer pain and its influence on quality of life in an international cohort of patients with cancer. BMJ Support Palliat Care. 2016;344–352.
   PubMed Web of Science ®Google Scholar
• Davies A, Buchanan A, Zeppetella G, et al. Breakthrough cancer pain: an observational study of 1000European oncology patients. J Pain Symptom Manage. 2013;46:619–628.
   PubMed Web of Science ®Google Scholar
• Portenoy RK, Payne D, Jacobson P. Breakthrough pain: characteristics and impact in patients with cancer pain. Pain. 1999;81:129–134.
   PubMed Web of Science ®Google Scholar
• Hanks GW, De Conno F, Cherny N, et al. Morphine and alternative opioids in cancer pain: the EAPC recommendations. Br J Cancer. 2001;587–593.
   PubMed Web of Science ®Google Scholar
• www.nice.org.uk/cg140
   Google Scholar
• Zeppetella G. Dynamics of breakthrough pain vs pharmacokinetics of oral morphine: implications for management. Eur J Cancer Care. 2009;331–337.
   PubMed Web of Science ®Google Scholar
• Mercadante S. Intravenous morphine for management of cancer pain. Lancet Oncol. 2010;11:484–489.
   PubMed Web of Science ®Google Scholar
• Mercadante S. Pharmacotherapy for breakthrough cancer pain. Drugs. 2012;181–190.
   PubMedGoogle Scholar
• Jandhyala R, Fullarton JR, Bennett MI. Efficacy of rapid-onset oral fentanyl formulations vs. oral morphine for cancer-related breakthrough pain: a meta-analysis of comparative trials. J Pain Symptom Manage. 2013;573–580.
   PubMed Web of Science ®Google Scholar
• Zeppetella G. Evidence-based treatment of cancer-related breakthrough pain with opioids. J Natl Compr Canc Netw. 2013;S37–S43.
   PubMed Web of Science ®Google Scholar
• Aronoff GA, Brennan MJ, Pritchard DD, et al. Evidence-based oral transmucosal fentanyl citrate (OTFC) dosing guidelines. Pain Med. 2005;305–314.
   PubMed Web of Science ®Google Scholar
• Schug SA, Ting S. Fentanyl formulations in the management of pain: an update. Drugs. 2017;77:747–763.
   PubMed Web of Science ®Google Scholar
• Farrar J, Cleary J, Rauck R, et al. Oral transmucosal fentanyl citrate: a randomized, double-blinded, placebo-controlled trial for treatment of breakthrough pain in cancer patients. J Natl Cancer Inst. 1998;90:611–616.
   PubMed Web of Science ®Google Scholar
• Portenoy RK, Payne R, Coluzzi P, et al. Oral transmucosal fentanyl citrate (OTFC) for the treatment of breakthrough pain in cancer patients: a controlled dose titration study. Pain. 1999;79:303–312.
   PubMed Web of Science ®Google Scholar
• Christie J, Simmonds M, Patt R, et al. Dose-titration multicenter study of transmucosal fentanyl citrate for the treatment of breakthrough pain in cancer patients using transdermal fentanyl for persistent pain. J Clin Oncol. 1998;16:3238–3245.
   PubMed Web of Science ®Google Scholar
• Payne R, Coluzzi P, Hart L, et al. Long-term safety of transmucosal fentanyl citrate for breakthrough cancer pain. J Pain Symptom Manage. 2001;115:575–583.
   PubMed Web of Science ®Google Scholar
• Blick S, Wagstaff AJ. Fentanyl buccal tablets in breakthrough pain in opioid-tolerant patients with cancer. Drugs. 2006;66:2387–2393.
   PubMed Web of Science ®Google Scholar
• Portenoy RK, Taylor D, Messina J, et al. A randomized, placebo-controlled study of fentanyl buccal tablet for breakthrough pain in opioid-treated patients with cancer. Clin J Pain. 2006;5:805–811.
   PubMed Web of Science ®Google Scholar
• Slatkin NE, Xie F, Messina J, et al. Fentanyl buccal tablet for relief of breakthrough pain in opioid-tolerant patients with cancer-related chronic pain. J Support Oncol. 2007;155:327–334.
   PubMedGoogle Scholar
• Weinstein SM, Messina J, Xie F. Fentanyl buccal tablet for the treatment of breakthrough pain in opioid-tolerant patients with chronic cancer pain: a long-term, open-label safety study. Cancer. 2009;2571–2579.
   PubMed Web of Science ®Google Scholar
• Lennernas B, Frank-Lissbrant I, Lennernas H, et al. Sublingual administration of fentanyl to cancer patients is an effective treatment for breakthrough pain: results from a randomized phase II study. Palliat Med. 2010;286–293.
   PubMed Web of Science ®Google Scholar
• Rauck R, Tark M, Reyes E, et al. Efficacy and long-term tolerability of sublingual fentanyl orally disintegrating tablet in the treatment of breakthrough cancer pain. Curr Med Res Opin. 2009;2877–2885.
   PubMed Web of Science ®Google Scholar
• Nalamachu SR, Narayana A, Janka L. Long-term dosing, safety, and tolerability of fentanyl buccal tablet in the management of noncancer-related breakthrough pain in opioid-tolerant patients. Curr Med Res Opin. 2011;751–760.
   PubMed Web of Science ®Google Scholar
• Vasisht N, Gever LN, Tagarro I, et al. Single-dose pharmacokinetics of fentanyl buccal soluble film. Pain Med. 2010;11:1017–1023.
   PubMed Web of Science ®Google Scholar
• Rauck R, North J, Gever LN, et al. Fentanyl buccal soluble film (FBSF) for breakthrough pain in patients with cancer: a randomized, double-blind, placebo-controlled study. Ann Oncol. 2010;21:1308–1314.
   PubMedGoogle Scholar
• Watts P, Smith A. PecSys: in situ gelling system for optimised nasal drug delivery. Expert Opin Drug Deliv. 2009;6:543–552.
   PubMed Web of Science ®Google Scholar
• Kress HG, Ororiska A, Kaczmarek Z, et al. Efficacy and tolerability of intranasal spray 50 to 200µg for breakthrough pain in patients with cancer: a phase III, multinational, randomized, double-blind, placebo-controlled, crossover trial with a 10-month, open-label extension treatment period. ClinTher. 2009;31:1177–1191.
   Google Scholar
• Portenoy RK, Burton AW, Gabrail N, et al. A multicenter, placebo-controlled, double-blind, multiple-crossover study of fentanyl pectin nasal spray in the treatment of breakthrough cancer pain. Pain. 2010;41:617–624.
   PubMed Web of Science ®Google Scholar
• Davies A, Sitte T, Elsner F, et al. Consistency of efficacy, patients acceptability, and nasal tolerability of fentanyl pectin nasal spray compared with immediate-release morphine sulphate in breakthrough cancer pain. J Pain Symptom Manage. 2011;41:358–366.
   PubMed Web of Science ®Google Scholar
• Mercadante S, Radbruck L, Davies A, et al. A comparison of intranasal fentanyl spray with oral transmucosal fentanyl citrate for the treatment of breakthrough cancer pain: an open-label, randomized, crossover trial. Curr Med Res Opin. 2009;2805–2815.
   PubMed Web of Science ®Google Scholar
• Portenoy RK, Raffaeli W, Torres L, et al. Long-term safety, tolerability, and consistency of effect of fentanyl pectin nasal spray for breakthrough cancer pain in opioid-tolerant patients. J Opioid Manage. 2010;6:319–328.
   PubMedGoogle Scholar
• Mercadante S, Vellucci R, Cuomo A, et al. Long-term efficacy and tolerability of intranasal fentanyl in the treatment of breakthrough cancer pain. Support Care Cancer. 2015;23:1349–1354.
   PubMed Web of Science ®Google Scholar
• Mercadante S. The use of rapid onset opioids for breakthrough cancer pain: the challenge of its dosing. Crit Rev Oncol Hematol. 2011;80:460–465.
   PubMed Web of Science ®Google Scholar
• Mercadante S, Prestia G, Adile C, et al. Intranasal fentanyl versus fentanyl pectin nasal spray for the management of breakthrough cancer pain in doses proportional to basal opioid regimen. J Pain. 2014;602–607.
   PubMed Web of Science ®Google Scholar
• Mercadante S. Breakthrough pain: on the road again. Eur J Pain. 2009;13:329–330.
   PubMed Web of Science ®Google Scholar
• Mercadante S, Gatti A, Porzio G, et al. Dosing fentanyl buccal tablet for breakthrough cancer pain: dose titration versus proportional doses. Curr Med Res Opin. 2012;28:963–968.
   PubMed Web of Science ®Google Scholar